Summary
Complete toxicological screening with aniracetam, a nootropic agent, showed the drug to be very well tolerated by mice, rats, rabbits and dogs, after both single and repeated dose administration. No adverse effects on the reproductive system were seen and the compound was negative in a battery of mutagenicity tests. Lifelong treatment in mice and rats did not reveal any carcinogenic potential of the drug. The effects found in the various animal studies occurred only at extremely high doses and were in general of minor toxicological relevance. The therapeutic index of the compound is therefore considered to be very large.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research 31: 345–364, 1975
Anonymous. Aniracetam. Drugs of the Future 6: 127–128, 1981
Anonymous. Aniracetam. Drugs of the Future 8: 251–252, 1983a
Anonymouse. Pramiracetam hydrochloride. Drugs of the Future 8: 795–796, 1983b
Anonymous. Aniracetam. Drugs of the Future 9: 211–212, 1984
Barrow WV, Taylor WJ. A rapid method for detecting malformations in rat fetuses. Journal of Morphology 127: 291–305, 1969
Cumin R, Bandle EF, Gamzu E, Haefely WE. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78: 104–111, 1982
Dawson AA. A note on the staining of the skeleton of cleared specimens with alizarin Red S. Stain Technology 1: 123–124, 1926
De Angelis L. Oxiracetam. Drugs of the Future 5: 405–407, 1980
De Angelis L. Etiracetam. Drugs of the Future 6: 552–553, 1981
Frantz CN, Mailing HV. The quantitative microsomal mutagenesis assay method. Mutation Research 31: 365–380, 1975
Green MHL, Bridges BA, Rogers AM, Horspool G, Muriel WJ, et al. Mutagen screening by a simplified bacterial fluctuation test: use of microsomal preparations and whole liver cells for metabolic activation. Mutation Research 48: 287–294, 1977
Ishidate M, Sofuni T, Yoshikawa K. Chromosomal aberration test in vitro as a primary screening test for environmental mutagens and/or carcinogens. GANN Monograph Cancer Research 27: 95–108, 1981
Moos WH, Davis RE, Schwarz RD, Gamzu ER. Cognition activators. Medical Research Reviews 8: 353–359, 1988
Poschel BPH, Marriott JG, Gluckman MI. Pharmacology of the cognition activator pramiracetam (CI-879). Drugs Under Experimental and Clinical Research 9: 853–871, 1983
Salewski E. Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. Archiv für experimentelle Pathologie und Pharmakologie 247: 367, 1964
Schildler U, Rush DK, Fielding S. Nootropic drugs: animal models for studying effects on cognition. Drug Development Research 4: 567–576, 1984
van Julsingha EB, Bennett CG. A dissecting procedure for the detection of anomalies in the rabbit foetal head. In Neubert D, et al. (Eds) Methods in prenatal toxicology, pp. 126–144, Thieme, Stuttgart, 1977
Zimmermann FK, Kern R, Rasenberger H. A yeast strain for simultaneous detection of induced mitotic crossing over, mitotic gene conversion and reverse mutation. Mutation Research 28: 381–388, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schläppi, B., Bürgin, H. & Gocke, E. Aniracetam. Drug Invest 5 (Suppl 1), 50–67 (1993). https://doi.org/10.1007/BF03258427
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258427